PPV23 vaccine is effective against pneumococcal disease in the elderly

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.
Takeaway
  • The 23-valent pnsumococcal polysaccharide vaccine (PPV23; Prevnar) is effective against invasive pneumococcal disease (IPD) and pneumoccal pneumonia in the elderly, according to a meta-analysis.
Why this matters
  • High rates of hospitalizations and mortality are observed in the 20-30% of cases of community-acquired pneumonia caused by pneumococcus.
Study design
  • 17 clinical trials, cohort studies and case-control studies met eligibility criteria after search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews.
  • Risk of bias was assessed.
  • Random effects meta-analysis was conducted.
  • Funding: No external funding was used.
Key results
  • For IPD, the pooled vaccine effectiveness (VE) in adults ≥60 y was 73% (95% CI, 10%-92%) in 4 clinical trials, 45% (95% CI, 15%-65%) in 3 cohort studies, and 59% (95% CI, 35%-74%) in 3 case-control studies.
  • For pneumococcal pneumonia, the pooled VE in adults ≥60 y was 64% (95% CI, 35%-80%) in 2 clinical trials and 48% (95% CI, 25%-63%) in 2 cohort studies.
Limitations
  • Few clinical trials met eligibility criteria.